Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells-Reference-Cited by-同舟云学术

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

Published:2021-08-19 Issue:12 Volume:20 Page:2329-2340
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Okajima Daisuke,Yasuda Satoru,Maejima Takanori^ORCID,Karibe Tsuyoshi,Sakurai Ken,Aida Tetsuo,Toki Tadashi^ORCID,Yamaguchi Junko,Kitamura Michiko,Kamei Reiko,Fujitani Tomomichi,Honda Tomoyo,Shibutani Tomoko,Muramatsu Sumie,Nakada Takashi,Goto Riki,Takahashi Shu,Yamaguchi Miki,Hamada Hirofumi,Noguchi Yutaka,Murakami Masato,Abe Yuki,Agatsuma Toshinori^ORCID

Funder

Daiichi-Sankyo

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel antibody-drug conjugates based on DXd-ADC technology;Bioorganic Chemistry;2024-10

2. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma;Gynecologic Oncology;2024-10

3. Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial;Nature Medicine;2024-09-14

4. Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial;Nature Medicine;2024-09-14

5. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01;Journal of Clinical Oncology;2024-09-12